Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free FNCH Stock Alerts

Finch Therapeutics Group (FNCH) Competitors

Finch Therapeutics Group logo
$7.45 0.00 (0.00%)
As of 05/22/2026
Compare

FNCH vs. TLPH, XLO, IXHL, NBRV, and ZYBT

Should you buy Finch Therapeutics Group stock or one of its competitors? MarketBeat compares Finch Therapeutics Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Finch Therapeutics Group include Talphera (TLPH), Xilio Therapeutics (XLO), Incannex Healthcare (IXHL), Nabriva Therapeutics (NBRV), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Finch Therapeutics Group compare to Talphera?

Talphera (NASDAQ:TLPH) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Talphera has higher revenue and earnings than Finch Therapeutics Group. Talphera is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talphera$30K1,384.00-$14.29M-$0.31N/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

Talphera currently has a consensus price target of $3.00, suggesting a potential upside of 275.00%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Talphera had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Talphera and 0 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 beat Talphera's score of -0.19 indicating that Finch Therapeutics Group is being referred to more favorably in the news media.

Company Overall Sentiment
Talphera Neutral
Finch Therapeutics Group Neutral

Talphera has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Finch Therapeutics Group's return on equity of -69.14% beat Talphera's return on equity.

Company Net Margins Return on Equity Return on Assets
TalpheraN/A -92.98% -53.22%
Finch Therapeutics Group N/A -69.14%-26.92%

37.7% of Talphera shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Talphera beats Finch Therapeutics Group on 8 of the 14 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Finch Therapeutics Group has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Finch Therapeutics Group's return on equity of -69.14% beat Xilio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xilio Therapeutics-58.52% -151.42% -27.61%
Finch Therapeutics Group N/A -69.14%-26.92%

Xilio Therapeutics presently has a consensus target price of $28.00, indicating a potential upside of 235.33%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Xilio Therapeutics is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xilio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Xilio Therapeutics has higher revenue and earnings than Finch Therapeutics Group. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xilio Therapeutics$43.77M1.14-$35.04M-$3.55N/A
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A

Xilio Therapeutics has a beta of -0.16, indicating that its share price is 116% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

In the previous week, Xilio Therapeutics' average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.

Company Overall Sentiment
Xilio Therapeutics Neutral
Finch Therapeutics Group Neutral

Summary

Xilio Therapeutics beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Incannex Healthcare?

Finch Therapeutics Group (NASDAQ:FNCH) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Incannex Healthcare has higher revenue and earnings than Finch Therapeutics Group. Incannex Healthcare is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Incannex Healthcare$90K446.88-$46.88M-$1.55N/A

In the previous week, Incannex Healthcare had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for Incannex Healthcare and 0 mentions for Finch Therapeutics Group. Incannex Healthcare's average media sentiment score of 0.63 beat Finch Therapeutics Group's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Incannex Healthcare Positive

Finch Therapeutics Group's return on equity of -69.14% beat Incannex Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Incannex Healthcare N/A -81.01%-76.11%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Incannex Healthcare
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 7.22, meaning that its share price is 622% more volatile than the broader market.

Summary

Incannex Healthcare beats Finch Therapeutics Group on 7 of the 12 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Nabriva Therapeutics?

Finch Therapeutics Group (NASDAQ:FNCH) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Nabriva Therapeutics has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Nabriva Therapeutics Neutral

Finch Therapeutics Group has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Finch Therapeutics Group's return on equity of -69.14% beat Nabriva Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Nabriva Therapeutics -148.11%-365.53%-135.81%

Summary

Finch Therapeutics Group beats Nabriva Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Zhengye Biotechnology?

Finch Therapeutics Group (NASDAQ:FNCH) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Zhengye Biotechnology has higher revenue and earnings than Finch Therapeutics Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Zhengye Biotechnology$16.64M2.45-$9.98MN/AN/A

In the previous week, Finch Therapeutics Group's average media sentiment score of 0.00 equaled Zhengye Biotechnology'saverage media sentiment score.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Zhengye Biotechnology Neutral

Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.47, suggesting that its share price is 347% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Zhengye Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

21.8% of Finch Therapeutics Group shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zhengye Biotechnology's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Zhengye Biotechnology N/A N/A N/A

Summary

Zhengye Biotechnology beats Finch Therapeutics Group on 5 of the 8 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNCH vs. The Competition

Export
MetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$11.97M$309.70M$6.46B$12.34B
Dividend YieldN/AN/A2.75%5.28%
P/E Ratio-0.84N/A21.0725.81
Price / SalesN/A185.14555.4388.28
Price / CashN/A22.4443.4956.67
Price / Book0.524.7910.367.17
Net Income-$74.75M-$132.96M$3.56B$336.99M
7 Day PerformanceN/A2.28%4.45%4.51%
1 Month Performance-2.74%30.58%1.86%3.09%
1 Year Performance-42.69%76.38%34.79%37.67%

Finch Therapeutics Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNCH
Finch Therapeutics Group
N/A$7.45
flat		N/AN/A$11.97MN/AN/A190
TLPH
Talphera
3.2621 of 5 stars		$0.90
-0.4%		$3.00
+234.3%		+61.1%$46.78M$30KN/A19
XLO
Xilio Therapeutics
3.1976 of 5 stars		$8.81
+13.5%		$28.00
+217.8%		-33.3%$46.43M$43.77MN/A70
IXHL
Incannex Healthcare
0.9117 of 5 stars		$3.88
+0.8%		N/A-46.1%$45.94M$90KN/A3
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59MN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FNCH) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Trump Is Eyeing the Biggest Monetary Shift Since Nixon
On August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...
Americas Gold Company | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Elon Confirms SpaceX IPO For 6/12 [Act Now!]
Elon Musk has confirmed SpaceX will IPO on Friday, June 12, 2026, at a valuation of up to $2 trillion - potent...
Paradigm Press | Sponsoredtc pixel
I was right about SpaceX. Now here's the part that matters
Goldman Sachs and JP Morgan have already been tied to allocations surrounding the SpaceX deal. When the bigges...
The Oxford Club | Sponsoredtc pixel